Search research articles
Contact Us
Filters
Showing results (251-260 of 283) with videos related to
Page
of 29
Sort By:
Journal of Cancer
|
June 22, 2026
Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors
Mingjia Li, Daniel J Spakowicz, Songzhu Zhao, et al.
The Lancet. Oncology
|
January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 1, 2025
Corrigendum to "The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic Oncology Vol. 20 No. 10: 1423-1440]"
David P Carbone, Fred R Hirsch, Raymond Uyiosa Osarogiagbon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2012
ROS1 rearrangements define a unique molecular class of lung cancers
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, et al.
The European Respiratory Journal
|
July 9, 2016
Defining a standard set of patient-centred outcomes for lung cancer
Kimberley S Mak, Annelotte C M van Bommel, Caleb Stowell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 20, 2021
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Angel Qin, Songzhu Zhao, Abdul Miah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer
Daniel Morgensztern, Neal Ready, Melissa L Johnson, et al.
Journal of Hematology & Oncology
|
May 18, 2022
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients
Zhen Zhou, Zhengping Ding, Jie Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 14, 2023
Germline <i>EGFR</i> Mutations and Familial Lung Cancer
Geoffrey R Oxnard, Ruthia Chen, Jennifer C Pharr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Hossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Page
of 29
Search research articles
Search
Showing results (251-260 of 283) with videos related to
Sort By:
Page
of 29
Journal of Cancer
|
June 22, 2026
Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors
Mingjia Li, Daniel J Spakowicz, Songzhu Zhao, et al.
The Lancet. Oncology
|
January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 1, 2025
Corrigendum to "The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic Oncology Vol. 20 No. 10: 1423-1440]"
David P Carbone, Fred R Hirsch, Raymond Uyiosa Osarogiagbon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2012
ROS1 rearrangements define a unique molecular class of lung cancers
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, et al.
The European Respiratory Journal
|
July 9, 2016
Defining a standard set of patient-centred outcomes for lung cancer
Kimberley S Mak, Annelotte C M van Bommel, Caleb Stowell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 20, 2021
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Angel Qin, Songzhu Zhao, Abdul Miah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer
Daniel Morgensztern, Neal Ready, Melissa L Johnson, et al.
Journal of Hematology & Oncology
|
May 18, 2022
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients
Zhen Zhou, Zhengping Ding, Jie Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 14, 2023
Germline <i>EGFR</i> Mutations and Familial Lung Cancer
Geoffrey R Oxnard, Ruthia Chen, Jennifer C Pharr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Hossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Page
of 29